SCHEMBL1368264

SCHEMBL1368264

COc1ccc(/C=C\C(=O)CC(=O)c2cc3ccc(OC)cc3sc2=O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.58
BACE1 P56817 4/20 0.48
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
TOP2A P11388 3/20 0.46
MAPT P10636 6/20 0.44
APP P05067 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
ABCG2 Q9UNQ0 2/20 0.44
MEN1 O00255 2/20 0.44
MAPK1 P28482 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
TNFRSF1A P19438 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1368220 1.00 GSK3B (0.58) GSK3BBACE1RAB9ANPC1TOP2A
SCHEMBL1368218 1.00 GSK3B (0.58) GSK3BBACE1RAB9ANPC1TOP2A
SCHEMBL1368079 0.92 GSK3B (0.53) GSK3BBACE1RAB9ANPC1TOP2A
SCHEMBL1369279 0.92 GSK3B (0.53) GSK3BBACE1RAB9ANPC1TOP2A
SCHEMBL1368434 0.92 GSK3B (0.53) GSK3BBACE1RAB9ANPC1MAPT
SCHEMBL1368031 0.92 GSK3B (0.53) GSK3BBACE1RAB9ANPC1MAPT
SCHEMBL1368030 0.92 GSK3B (0.53) GSK3BBACE1RAB9ANPC1MAPT
SCHEMBL1368082 0.92 GSK3B (0.53) GSK3BBACE1RAB9ANPC1TOP2A
SCHEMBL4344624 0.86 ABCG2 (0.57) RAB9AMAPTAPPSMN1; SMN2ABCG2
SCHEMBL1368032 0.86 ABCG2 (0.57) RAB9AMAPTAPPSMN1; SMN2ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US claimed
WO-2006132947-A2 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2006-12-14 WO claimed
US-8067461-B2 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-11-29 US disclosed
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275650-A1 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof NQO2, NQO1, HCCS GSK3B 4183/4885BACE1 4687/4885RAB9A 1991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.